Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.

ABSTRACT:

Background.

The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown.

Methods.

We use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and the Centers for Disease Control and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting a raltegravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate). We account for confounding and selection bias as well as generalizability by standardization for measured variables, and present both observational intent-to-treat and per-protocol estimates.

Results.

At treatment initiation, 12% of patients were female, 36%

SUBMITTER: Cole SR 

PROVIDER: S-EPMC6059161 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature